

**Supplementary Table S1:** All chemotherapy agents available for 1,419 survivors of childhood cancer

Chemotherapy Agent	Count	Percentage
Anti-rejection drugs (Sirolimus Tacrolimus MMF)	13	0.1
Antithymocyte globulin [ATG/ATGAM]	2	< 0.1
Arsenic trioxide (Trisinox)	4	< 0.1
Asparaginase E-Coli (L-Asp) Elspar Kidrolase	125	1.2
Asparaginase Erwinia (Erwinase)	56	0.5
Asparaginase Peg	355	3.4
Azacytidine (Aza-C) 5-AZA 5-AC 5-azacytidine)	2	< 0.1
Bevacizumab (Avastin)	4	< 0.1
Bleomycin Blenoxane Bleo*	96	0.9
Blinatumomab	1	< 0.1
Bortezomib (Velcade)	2	< 0.1
Brentuximab vedotin (SGN-35)	5	< 0.1
Busulphan Busulfan (Myleran)*	4	< 0.1
Carboplatin CBDCA Paraplatin Carboplatinum	208	2
Carmustine (BCNU) Bis-Chloroethyl-Nitrosourea BiCNU*	2	< 0.1
Ch14.18 (Dinutuximab)	13	0.1
Cisplatin CDDP Platinol Cisplatinum Cis-diamminedicloro-platinum II P*	232	2.2
Cladribine CdA Leustatin	4	< 0.1
Clofarabine Clolar	13	0.1
Colony stimulating factors/Erythropoietin (e.g., G-CSF Eprex Aransep)	384	3.7
Crizotinib	2	< 0.1
Cyclophosphamide Cytoxan CTX Procytox*	836	8.1
Cyclosporin	55	0.5
Cytarabine (IM sub q PO OR IV) Ara-C Cytosar Cytosine arabinoside	435	4.2
Cytarabine (IT ONLY) Ara-C Cytosar Cytosine arabinoside	556	5.4
Cytarabine (ONLY IV >=500mg/m2 per dose) Ara-C Cytosar Cytosine arabinoside	146	1.4
Dabrafenib	2	< 0.1
Dactinomycin (DACT) Actinomycin D Cosmogen Act-D	154	1.5
Dasatinib (BMS-354825)	6	0.1
Daunomycin Daunorubicin Cerubidine DNR*	299	2.9
Dexamethasone (Decadron)	474	4.6
Dexrazoxane Zinecard Cardioxane	24	0.2
Docetaxel (Taxotere)	4	< 0.1
Dolastatin 10 (D10)	1	< 0.1
Doxorubicin Adriamycin ADR*	785	7.6
Doxorubicin-pegylated liposomal (DOXIL) PLD*	4	< 0.1
Erlotinib Tarceva OSI-774	3	< 0.1
Etoposide (VP16) VePesid ETOP*	563	5.4
Etoposide phosphate	3	< 0.1
Fludarabine FAMP Fludara	30	0.3
Fluorouracil (5-FU Adrucil Efudex Fluoroplex 5-fluorouracil)	35	0.3
Gamma globulin	68	0.7

Chemotherapy Agent	Count	Percentage
Gemcitabine (Gemzar)	12	0.1
Gemtuzumab (Mylotarg)	6	0.1
Hu14.18-IL2	2	< 0.1
Hydrocortisone (IT ONLY)	112	1.1
Hydroxyurea Hydroxycarbamide Hydrea	6	0.1
Idarubicin Idamycin 4-Demethoxydaunorubicin*	28	0.3
Ifosfamide Isophosphamide IFOS Ifex Holoxan*	217	2.1
Imatinib (Gleevec) IMAT	11	0.1
Inotuzumab	1	< 0.1
Interferon	2	< 0.1
Interleukin-2	11	0.1
Irinotecan (CPT-11) Camptosar	52	0.5
Isotretinoin 13-cis-Retinoic Acid	44	0.4
Ixabepilone	1	< 0.1
Lestaurtinib (CEP-701)	1	< 0.1
Lomustine (CCNU) CeeNU Chloroethyl-Cyclohexyl-Nitrosurea*	20	0.2
Melphalan L-PAM Alkeran L-sarcosine*	5	< 0.1
Mercaptopurine (6-MP Purinethol 6-mercaptopurine	433	4.2
Methotrexate (IM PO Sub q IC OR IV<500mg/m2) MTX amethopterin	428	4.1
Methotrexate (IT ONLY) MTX amethopterin	558	5.4
Methotrexate (IV >=500mg/m2 ONLY) MTX amethopterin*	354	3.4
Mitotane Lysodren	2	< 0.1
Mitoxantrone Novantrone DHAD Dihydrochloride*	57	0.6
Nelarabine (Arranon AraG)	13	0.1
Nimotuzumab	2	< 0.1
Other	28	0.3
Oxaliplatin Eloxatin	4	< 0.1
Paclitaxel Taxol	4	< 0.1
Pembrolizumab	1	< 0.1
Prednisone (Methylprednisone Prednisolone)	376	3.6
Procarbazine PCB Natulan Matulane*	7	0.1
Rituximab Rituxan	24	0.2
Sorafenib BAY 43-9006 Nexavar	8	0.1
Tamoxifen Tam Nolvadex	2	< 0.1
Temozolomide TMZ Temodal	52	0.5
Teniposide (Vumon) VM-26*	21	0.2
Thioguanine (6-TG Lanvis 6-thioguanine)	304	2.9
Thiotepa TESP Triethylene Thiophosphoramide*	12	0.1
Topotecan (Hycamtin)	60	0.6
Trametinib	2	< 0.1
Tretinoin ATRA all-trans-Retinoic acid Vesanoid	8	0.1
Vinblastine Velbe Velban VLB	57	0.6
Vincristine Leurocristine Oncovin VCR	974	9.4

Chemotherapy Agent	Count	Percentage
Vinorelbine Navelbine	20	0.2
Vorinostat	1	< 0.1

\* Presented data based on treatment information available as of May 4<sup>th</sup>, 2022 (for Alberta Children's Hospital) and November 30<sup>th</sup>, 2022 (for Stollery Children's Hospital).